Dose-escalation in the picture: pharmacological and imaging studies in depression
Ruhé, H.G.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Contents

Part I. General introduction 9

1. General introduction and outline of the thesis 11
2. Design and methods of the DELPHI-study 31

Part II. Studies to guide clinical treatment of Major Depressive Disorder 41

3. Clinical use of the Hamilton Depression Rating Scale: Is increased efficiency possible? A post hoc comparison of HDRS, Maier and Bech subscales, CGI and SCL-90 scores. 43
   Comprehensive Psychiatry 2005; 46: 417-427

4. Dose-escalation for insufficient response to a standard dose of a selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. 59
   British Journal of Psychiatry 2006; 189: 309-316

5. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review 73
   Journal of Clinical Psychiatry 2006; 67: 1836-1855

Part III. Serotonin in the etiology of Major Depressive Disorder 99

6. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies 101
   Molecular Psychiatry 2007; 12: 331-359

7. Serotonin transporter binding with [^{123}I]β-CIT SPECT in major depressive disorder versus controls: effect of season and gender. 139
   Submitted
Part IV. Neurobiological effects of paroxetine in the treatment of Major Depressive Disorder

8. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder 157
   *Pharmacogenetics and Genomics 2008; in press*

9. Evidence why paroxetine dose-escalation is not effective in major depressive disorder: a randomized-controlled trial with assessment of serotonin transporter occupancy 173
   *Neuropsychopharmacology 2008; in press*

10. Successful pharmacological treatment of major depressive disorder attenuates amygdala activation to negative facial expressions. An fMRI study 195
   *Submitted*

11. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism 217
   *Journal of Thrombosis and Haemostasis 2008; in press*

Part V. Summary and general discussion

12. Summary, conclusions and general discussion 233
13. Samenvatting en conclusies 253

Part VI. Abbreviations, color figures, publications, acknowledgement and curriculum vitae

Abbreviations 271
Color figures 275
Publications 285
Dankwoord 291
Curriculum Vitae 297